$2.560
-0.244 (-9.54%)Zum Schluss
LUNG-News
LUNG-Events
Pulmonx Expects 2026 Revenue of $90M to $92M
The company said, "Pulmonx continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company now expects gross margin for the full year 2026 to be approximately 77%. Pulmonx now expects total operating expenses for the full year 2026 to fall within the range of $108 million to $109 million, inclusive of approximately $14 million of non-cash stock-based compensation. The Company now expects cash, cash equivalents, and marketable securities to decrease by approximately $22 million for the full year 2026 assuming no additional drawdowns under the Company's credit facility."
Pulmonx Reports Q3 Revenue of $22.84M, Beating Consensus
Reports Q3 revenue $22.84M, consensus $21.94M. "We are very pleased to have returned to year-over-year revenue growth in the third quarter. We continue to execute on our commercial strategy, advance our clinical initiatives, and deliver the operating leverage we expected," said Glen French, President and Chief Executive Officer of Pulmonx. "With a fully staffed U.S. sales leadership team, a more focused global commercial team, and a realigned cost structure, we are confident in our ability to build on this momentum and deliver growth while advancing our longer-term strategic priorities."
Pulmonx Reports Q2 Revenue of $22.75M, Exceeds Expectations
Reports Q2 revenue $22.75M, consensus $22.39M. "We are pleased with the progress we made in the second quarter executing our commercial strategy, advancing our clinical initiatives, and beginning to deliver the significant operating leverage we expected," said Glen French, President and Chief Executive Officer of Pulmonx. "With a fully staffed US sales leadership team, a more focused global commercial team, and a realigned cost structure, we are confident in our ability to return to year-over-year revenue growth and drive meaningful operating leverage while advancing our longer-term strategic priorities."
Pulmonx Expects 2026 Revenue of $90M to $92M
The company said, "Pulmonx continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company now expects gross margin for the full year 2026 to be approximately 76%. Pulmonx now expects total operating expenses for the full year 2026 to fall within the range of $109 million to $111 million, inclusive of approximately $15 million of non-cash stock-based compensation. The Company continues to expect cash, cash equivalents, and marketable securities to decrease by approximately $23 million for the full year 2026 assuming no additional drawdowns under the Company's credit facility."
Pulmonx Expects 2026 Revenue Between $90 Million and $92 Million
The company said, "Pulmonx continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company continues to expect gross margin for the full year 2026 to be approximately 75%. Pulmonx continues to expect total operating expenses for the full year 2026 to fall within the range of $113 million to $115 million, inclusive of approximately $19 million of non-cash stock-based compensation. The Company continues to expect cash, cash equivalents, and marketable securities to decrease by approximately $23 million for the full year 2026 assuming no additional drawdowns under the Company's credit facility."
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.